Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.

Meng YuanYirui ZhaiYu MenJianyang WangLei DengWenqing WangYongxing BaoXu YangShuang SunZeliang MaYunsong LiuJianing WangHui ZhuZhouguang Hui

Published in: Thoracic cancer (2021)

Endostar combined with CCRT is associated with significantly higher ORR, DCR and survival rate than CCRT with similar incidences of main adverse events in NSCLC.

Keyphrases

advanced non small cell lung cancer
locally advanced
epidermal growth factor receptor
rectal cancer
squamous cell carcinoma
radiation therapy
free survival
recombinant human
small cell lung cancer
tyrosine kinase